Evoke Pharma, Inc. (EVOK)
USD 3.09
(6.19%)
USD 3.09
(6.19%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.64 Million USD | 24.22% |
| 2022 | 7.76 Million USD | 10.67% |
| 2021 | 7.01 Million USD | -44.52% |
| 2020 | 12.64 Million USD | 527.7% |
| 2019 | 2.01 Million USD | 23.29% |
| 2018 | 1.63 Million USD | -71.7% |
| 2017 | 5.77 Million USD | 4.89% |
| 2016 | 5.5 Million USD | -9.24% |
| 2015 | 6.06 Million USD | -0.75% |
| 2014 | 6.11 Million USD | 60.73% |
| 2013 | 3.8 Million USD | -80.77% |
| 2012 | 19.77 Million USD | 6.55% |
| 2011 | 18.55 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 8.95 Million USD | -7.17% |
| 2024 Q2 | 9.47 Million USD | 5.74% |
| 2023 Q2 | 8.44 Million USD | 6.67% |
| 2023 FY | 9.64 Million USD | 24.22% |
| 2023 Q4 | 9.64 Million USD | 10.56% |
| 2023 Q3 | 8.72 Million USD | 3.38% |
| 2023 Q1 | 7.91 Million USD | 1.88% |
| 2022 Q2 | 7.21 Million USD | 1.71% |
| 2022 FY | 7.76 Million USD | 10.67% |
| 2022 Q4 | 7.76 Million USD | -1.41% |
| 2022 Q1 | 7.09 Million USD | 1.06% |
| 2022 Q3 | 7.87 Million USD | 9.21% |
| 2021 Q4 | 7.01 Million USD | 2.06% |
| 2021 Q3 | 6.87 Million USD | -40.68% |
| 2021 Q2 | 11.59 Million USD | 0.93% |
| 2021 FY | 7.01 Million USD | -44.52% |
| 2021 Q1 | 11.48 Million USD | -9.2% |
| 2020 Q3 | 8.67 Million USD | 0.39% |
| 2020 Q1 | 1.71 Million USD | -14.83% |
| 2020 Q2 | 8.64 Million USD | 403.47% |
| 2020 Q4 | 12.64 Million USD | 45.82% |
| 2020 FY | 12.64 Million USD | 527.7% |
| 2019 Q3 | 2.15 Million USD | 67.64% |
| 2019 Q2 | 1.28 Million USD | -0.18% |
| 2019 Q1 | 1.28 Million USD | -21.23% |
| 2019 FY | 2.01 Million USD | 23.29% |
| 2019 Q4 | 2.01 Million USD | -6.46% |
| 2018 FY | 1.63 Million USD | -71.7% |
| 2018 Q1 | 1.19 Million USD | -79.3% |
| 2018 Q4 | 1.63 Million USD | 1.48% |
| 2018 Q3 | 1.61 Million USD | 27.23% |
| 2018 Q2 | 1.26 Million USD | 5.88% |
| 2017 Q3 | 8.69 Million USD | 36.23% |
| 2017 Q2 | 6.38 Million USD | -7.51% |
| 2017 FY | 5.77 Million USD | 4.89% |
| 2017 Q4 | 5.77 Million USD | -33.6% |
| 2017 Q1 | 6.9 Million USD | 25.38% |
| 2016 Q4 | 5.5 Million USD | -9.87% |
| 2016 FY | 5.5 Million USD | -9.24% |
| 2016 Q2 | 6.16 Million USD | 0.79% |
| 2016 Q3 | 6.11 Million USD | -0.86% |
| 2016 Q1 | 6.11 Million USD | 0.79% |
| 2015 Q1 | 6.18 Million USD | 1.22% |
| 2015 FY | 6.06 Million USD | -0.75% |
| 2015 Q4 | 6.06 Million USD | -4.82% |
| 2015 Q3 | 6.37 Million USD | 1.25% |
| 2015 Q2 | 6.29 Million USD | 1.75% |
| 2014 Q1 | 4.11 Million USD | 8.23% |
| 2014 Q2 | 1.85 Million USD | -54.96% |
| 2014 FY | 6.11 Million USD | 60.73% |
| 2014 Q4 | 6.11 Million USD | 259.55% |
| 2014 Q3 | 1.7 Million USD | -8.29% |
| 2013 Q4 | 3.8 Million USD | -15.77% |
| 2013 Q1 | 21.83 Million USD | 10.39% |
| 2013 Q2 | 3.72 Million USD | -82.92% |
| 2013 Q3 | 4.51 Million USD | 21.09% |
| 2013 FY | 3.8 Million USD | -80.77% |
| 2012 FY | 19.77 Million USD | 6.55% |
| 2012 Q4 | 19.77 Million USD | 0.0% |
| 2011 FY | 18.55 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 660.79 Million USD | 98.54% |
| Theratechnologies Inc. | 98.63 Million USD | 90.219% |
| Safety Shot Inc | 3.89 Million USD | -147.892% |
| Cosmos Health Inc. | 30.25 Million USD | 68.108% |
| Cronos Group Inc. | 43.73 Million USD | 77.94% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 98.82% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 80.084% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 94.68% |
| Universe Pharmaceuticals INC | 13.75 Million USD | 29.854% |
| ProPhase Labs, Inc. | 42.54 Million USD | 77.322% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -10.188% |
| Dynavax Technologies Corporation | 375.02 Million USD | 97.427% |
| Radius Health, Inc. | 804.29 Million USD | 98.8% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -4.909% |
| Alvotech | 1.88 Billion USD | 99.488% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -57.145% |
| Alpha Teknova, Inc. | 38.55 Million USD | 74.973% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 92.951% |
| SCYNEXIS, Inc. | 55.45 Million USD | 82.6% |
| Harrow Health, Inc. | 241.75 Million USD | 96.009% |
| Biofrontera Inc. | 23.13 Million USD | 58.304% |
| DURECT Corporation | 30.4 Million USD | 68.269% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 98.021% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 97.954% |
| OptiNose, Inc. | 194.33 Million USD | 95.035% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 54.009% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 94.114% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 81.628% |
| SIGA Technologies, Inc. | 57.97 Million USD | 83.359% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 95.611% |
| Shineco, Inc. | 47.6 Million USD | 79.732% |
| Phibro Animal Health Corporation | 725.54 Million USD | 98.67% |
| Procaps Group S.A. | 462.06 Million USD | 97.912% |
| TherapeuticsMD, Inc. | 14.02 Million USD | 31.193% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -4295.242% |
| Viatris Inc. | 27.21 Billion USD | 99.965% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -57.145% |
| Rockwell Medical, Inc. | 30.88 Million USD | 68.758% |
| Incannex Healthcare Limited | 5.83 Million USD | -65.49% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 89.325% |
| Tilray Brands, Inc. | 892.11 Million USD | 98.919% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 98.982% |
| PetIQ, Inc. | 645.22 Million USD | 98.505% |
| Silver Spike Investment Corp. | 3 Million USD | -220.552% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.054% |
| Journey Medical Corporation | 56.49 Million USD | 82.923% |
| Alimera Sciences, Inc. | 107.35 Million USD | 91.013% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 54.737% |
| Assertio Holdings, Inc. | 148.41 Million USD | 93.499% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -408.875% |
| Embecta Corp. | 2.03 Billion USD | 99.526% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -13.633% |
| Procaps Group, S.A. | 462.06 Million USD | 97.912% |
| PainReform Ltd. | 2.69 Million USD | -258.532% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 94.436% |
| Hempacco Co., Inc. | 18.82 Million USD | 48.741% |
| Talphera, Inc. | 6.29 Million USD | -53.388% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 98.63% |
| Alvotech | 1.88 Billion USD | 99.488% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 98.845% |
| Kamada Ltd. | 109.96 Million USD | 91.226% |
| Indivior PLC | 1.95 Billion USD | 99.506% |
| Currenc Group, Inc. | 177.67 Million USD | 94.57% |
| Flora Growth Corp. | 17.22 Million USD | 43.978% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -13.633% |
| Evolus, Inc. | 209.68 Million USD | 95.399% |
| HUTCHMED (China) Limited | 536.38 Million USD | 98.201% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 98.895% |
| Akanda Corp. | 12.66 Million USD | 23.844% |